C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
C4 Therapeutics, Inc. (CCCC)
NASDAQ:AMEX Investor Relations:
ir.chinacache.com
Company Research
Source: Yahoo! Finance
CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million as of December 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended December 31, 2024, as well as business updates. “In 2024, C4T made significant progress across our degrader portfolio and our discovery collaborations. We shared clinical data from our two lead programs, where cem
Read more
Impact Snapshot
Event Time:
CCCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CCCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CCCC alerts
High impacting C4 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CCCC
News
- C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsGlobeNewswire
- C4 Therapeutics to Participate in Upcoming March Investor Conferences [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics to Participate in Upcoming March Investor ConferencesGlobeNewswire
- C4 Therapeutics, Inc. (NASDAQ: CCCC) was upgraded by analysts at UBS Group AG to a "hold" rating.MarketBeat
CCCC
Earnings
- 2/27/25 - Miss
CCCC
Analyst Actions
- 2/19/25 - UBS Group AG
CCCC
Sec Filings
- 4/3/25 - Form 4
- 4/3/25 - Form 4
- 2/27/25 - Form S-8
- CCCC's page on the SEC website